These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28457887)

  • 1. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.
    Gómez-Miragaya J; Palafox M; Paré L; Yoldi G; Ferrer I; Vila S; Galván P; Pellegrini P; Pérez-Montoyo H; Igea A; Muñoz P; Esteller M; Nebreda AR; Urruticoechea A; Morilla I; Pernas S; Climent F; Soler-Monso MT; Petit A; Serra V; Prat A; González-Suárez E
    Stem Cell Reports; 2017 May; 8(5):1392-1407. PubMed ID: 28457887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer.
    Gomez-Miragaya J; González-Suárez E
    Mol Cell Oncol; 2017; 4(4):e1338208. PubMed ID: 28868349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
    Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
    Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 12p Amplification in Triple-Negative/
    Gómez-Miragaya J; Díaz-Navarro A; Tonda R; Beltran S; Palomero L; Palafox M; Dobrolecki LE; Huang C; Vasaikar S; Zhang B; Wulf GM; Collado-Sole A; Trinidad EM; Muñoz P; Paré L; Prat A; Bruna A; Caldas C; Arribas J; Soler-Monso MT; Petit A; Balmaña J; Cruz C; Serra V; Pujana MA; Lewis MT; Puente XS; González-Suárez E
    Cancer Res; 2019 Aug; 79(16):4258-4270. PubMed ID: 31213465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells.
    Velázquez-Quesada I; Ruiz-Moreno AJ; Casique-Aguirre D; Aguirre-Alvarado C; Cortés-Mendoza F; de la Fuente-Granada M; García-Pérez C; Pérez-Tapia SM; González-Arenas A; Segura-Cabrera A; Velasco-Velázquez MA
    Drug Des Devel Ther; 2020; 14():1799-1811. PubMed ID: 32494122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.
    Matossian MD; Burks HE; Elliott S; Hoang VT; Bowles AC; Sabol RA; Wahba B; Anbalagan M; Rowan B; Abazeed ME; Bunnell BA; Moroz K; Miele L; Rhodes LV; Jones SD; Martin EC; Collins-Burow BM; Burow ME
    BMC Cancer; 2019 Mar; 19(1):205. PubMed ID: 30845999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
    Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
    Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells.
    Kai K; Iwamoto T; Kobayashi T; Arima Y; Takamoto Y; Ohnishi N; Bartholomeusz C; Horii R; Akiyama F; Hortobagyi GN; Pusztai L; Saya H; Ueno NT
    Oncogene; 2014 Jan; 33(4):440-8. PubMed ID: 23376849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
    Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
    Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 13. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
    Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
    Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer.
    Giró-Perafita A; Palomeras S; Lum DH; Blancafort A; Viñas G; Oliveras G; Pérez-Bueno F; Sarrats A; Welm AL; Puig T
    Clin Cancer Res; 2016 Sep; 22(18):4687-97. PubMed ID: 27106068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer.
    Cazet AS; Hui MN; Elsworth BL; Wu SZ; Roden D; Chan CL; Skhinas JN; Collot R; Yang J; Harvey K; Johan MZ; Cooper C; Nair R; Herrmann D; McFarland A; Deng N; Ruiz-Borrego M; Rojo F; Trigo JM; Bezares S; Caballero R; Lim E; Timpson P; O'Toole S; Watkins DN; Cox TR; Samuel MS; Martín M; Swarbrick A
    Nat Commun; 2018 Jul; 9(1):2897. PubMed ID: 30042390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.
    Chen W; Qin Y; Wang D; Zhou L; Liu Y; Chen S; Yin L; Xiao Y; Yao XH; Yang X; Ma W; Chen W; He X; Zhang L; Yang Q; Bian X; Shao ZM; Liu S
    PLoS Biol; 2018 Jul; 16(7):e2005869. PubMed ID: 30052635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clathrin-mediated endocytic uptake of PUFA enriched self-nanoemulsifying lipidic systems (SNELS) of an anticancer drug against triple negative cancer and DMBA induced preclinical tumor model.
    Khurana RK; Kumar R; Gaspar BL; Welsby G; Welsby P; Kesharwani P; Katare OP; Singh KK; Singh B
    Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():645-658. PubMed ID: 30033299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
    Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
    Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.